Drug Trial Radar · NCT05403450
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
33
Actual
Start
Feb 22, 2023
Primary completion
Dec 16, 2024
Study completion Jul 1, 2026
Sponsor
- Lead sponsor
- Taiho Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2. As no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria, Sponsor decided to halt recruitment and to not conduct Phase 2 of the study.
Conditions
- Relapsed/Refractory Peripheral T-cell Lymphoma
Interventions
TolinapantDrug
Capsule for oral administration
Decitabine + CedazuridineDrug
Tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs)Time frame: Up to 54 months
- Phase 2: Antitumor Activity Assessed by Overall Response Rate (ORR) Based on 2014 Lugano Classification Using Computerized Tomography (CT) Imaging as the Primary ModalityTime frame: Up to 54 months
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus Site #118
Aurora, Colorado
Moffitt Cancer Center Site #157
Tampa, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
NYU Langone Laura and Isaac Perlmutter Cancer Center Site #153
New York, New York
University of Pennsylvania Site# 160
Philadelphia, Pennsylvania
The University of Texas MD Anderson Cancer Center Site #101
Houston, Texas
Concord Hospital
Concord, New South Wales, Australia
Monash Medical Center
Melbourne, Victoria, Australia
Institut Bergonié Site#553
Bordeaux, France
Institut Paoli-Calmettes
Marseille, France
U.O.C. di Ematologia Pad. 8IRCCS Azienda OspedalieroUniversitaria di Bologna Site#651
Bologna, Italy
Fondazione IRCCS San Gerardo dei Tintori Site #655
Monza, Italy
Ośrodek Badań Klinicznych Wczesnych Faz - Uniwersyteckie Centrum Kliniczne w Gdańsku
Gdansk, Pomeranian Voivodeship, Poland
Hospital del Mar Site #704
Barcelona, Spain
Hospital Universitario Fundación Jiménez Díaz Site #703
Madrid, Spain
Hospital Universitario 12 de Octubre Site#710
Madrid, Spain
Hospital Universitario Marqués de Valdecilla Site#711
Santander, Spain
Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain
Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.